Table 1.

Criteria used by Health Canada in determination of priority review or Notice of Compliance with conditions pathway and by Human Drug Advisory Panel and Prescrire in determining innovation status

Health Canada: criteria for priority review and NOC/c pathway	Human Drug Advisory Panel of Patented Medicine Prices Review Board: – criteria for breakthrough and substantial improvement	Prescrire: criteria for bravo and a real advance
Priority review: a serious, life-threatening or severely debilitating illness or condition for which there is substantial evidence of clinical effectiveness that the drug provides: effective treatment, prevention or diagnosis of a disease or condition for which no drug is presently marketed in Canada	Breakthrough: first drug product to treat effectively a particular illness	Bravo: major therapeutic innovation in an area where previously no treatment was available
NOC/c pathway: provides patients suffering from serious, life-threatening or severely debilitating diseases or conditions with earlier access to promising new drugs	Substantial improvement: provides a substantial improvement over existing drug products	A real advance: product is an important therapeutic innovation but has certain limitations

Adapted from.²⁴

NOC/c, Notice of Compliance with conditions.